Q3 2015 13F Holders as of 9/30/2015
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
1.57B
-
Number of holders
-
40
-
Total 13F shares, excl. options
-
13.8M
-
Shares change
-
-4.96M
-
Total reported value, excl. options
-
$165M
-
Value change
-
-$63.3M
-
Number of buys
-
15
-
Number of sells
-
-21
-
Price
-
$11.97
Significant Holders of Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP) as of Q3 2015
49 filings reported holding ADAP - Adaptimmune Therapeutics PLC - Ordinary Shares as of Q3 2015.
Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP) has 40 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13.8M shares
of 1.57B outstanding shares and own 0.88% of the company stock.
Largest 10 shareholders include FMR LLC (4.82M shares), Foresite Capital Management II, LLC (1.76M shares), Capital World Investors (1.71M shares), Partner Fund Management, L.P. (1M shares), Rock Springs Capital Management LP (756K shares), CITADEL ADVISORS LLC (655K shares), JENNISON ASSOCIATES LLC (485K shares), ADAGE CAPITAL PARTNERS GP LLC (350K shares), QVT Financial LP (350K shares), and Tekla Capital Management LLC (282K shares).
This table shows the top 40 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.